



# **SOME DRUGS AND HERBAL PRODUCTS**

**VOLUME 108**

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 4–11 June 2013

Lyon, France - 2016

**IARC MONOGRAPHS  
ON THE EVALUATION  
OF CARCINOGENIC RISKS  
TO HUMANS**

# LIST OF PARTICIPANTS

---

## Members<sup>1</sup>

*Bruce C. Baguley*

Auckland Cancer Society Research Centre  
University of Auckland  
Auckland  
New Zealand

*Robert J. Biggar*

Queensland University of Technology  
Brisbane  
Australia

*Frederick A. Beland*

National Center for Toxicological Research  
Food and Drug Administration  
Jefferson, AR  
USA

*Esperanza J. Carcache de Blanco*

College of Pharmacy  
Ohio State University  
Columbus, OH  
USA

*Joseph M. Betz (Subgroup chair, Exposure  
Data)*

Office of Dietary Supplements  
National Institutes of Health  
Rockville, MD  
USA

*Michael L. Cunningham [retired]*

National Institute of Environmental Health  
Sciences  
Chapel Hill, NC  
USA

---

<sup>1</sup> Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only. Invited Specialists do not serve as Meeting Chair or Subgroup Chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations.

Each participant was asked to disclose pertinent research, employment, and financial interests. Current financial interests and research and employment interests during the past 4 years or anticipated in the future are identified here. Minor pertinent interests are not listed and include stock valued at no more than US \$1000 overall, grants that provide no more than 5% of the research budget of the expert's organization and that do not support the expert's research or position, and consulting or speaking on matters not before a court or government agency that does not exceed 2% of total professional time or compensation. All grants that support the expert's research or position and all consulting or speaking on behalf of an interested party on matters before a court or government agency are listed as significant pertinent interests.

*June K. Dunnick*

Toxicology Branch  
National Institute of Environmental Health  
Sciences  
Research Triangle Park, NC  
USA

*Dirk W. Lachenmeier*

Ministry of Rural Region and Consumer  
Protection Baden-Württemberg  
Stuttgart  
Germany

*Lei Guo*

National Center for Toxicological Research  
Food and Drug Administration  
Jefferson, AR  
USA

*Ruth M. Lunn*

National Toxicology Program  
National Institute of Environmental Health  
Sciences  
Research Triangle Park, NC  
USA

*Charles William Jameson (Subgroup Chair,  
Cancer in Experimental Animals)*

CWJ Consulting, LLC  
Cape Coral, FL  
USA

*M. Matilde Marques (Subgroup Chair,  
Mechanistic and Other Relevant Data)*

Department of Chemical and Biological  
Engineering  
Technical University of Lisbon  
Lisbon  
Portugal

*Margaret Karagas (Subgroup Chair, Cancer in  
Humans)*

Section of Biostatistics and Epidemiology  
Dartmouth Medical School  
Lebanon, NH  
USA

*David L. McCormick*

IIT Research Institute  
Chicago, IL  
USA

*Trudy L. Knight*

Institute of Occupational Environmental  
Medicine  
University of Birmingham  
Birmingham  
United Kingdom

*Sonal Singh*

Department of Epidemiology  
Johns Hopkins School of Medicine and Public  
Health  
Baltimore, MD  
USA

*Saranjit Singh [unable to attend]*

Department of Pharmaceutical Analysis  
National Institute of Pharmaceutical  
Education and Research  
Punjab  
India

*Bernard W. Stewart (Overall Chair)*

Cancer Control Program  
South Eastern Sydney Public Health Unit  
Randwick  
Australia

*Chin-Hsiao Tseng*<sup>2</sup>

College of Medicine  
Taiwan University  
Taipei  
Taiwan, China

*Hiroyuki Tsuda*

Nanotoxicology Project  
Nagoya City University  
Nagoya  
Japan

*Kristine L. Witt [unable to attend]*

National Toxicology Program  
National Institute of Environmental Health  
Sciences  
Research Triangle Park, NC  
USA

*Shufeng Zhou*

College of Pharmacy  
University of South Florida  
Tampa, FL  
USA

**Invited specialist***Randall S. Stafford*<sup>3</sup>

Program on Prevention Outcomes and  
Practices  
Stanford Prevention Research Center  
Stanford, CA  
USA

**Representatives**

None

**Observers***David Alexander*<sup>4</sup> *[unable to attend]*

Williams Kherkher Hart Boundas, LLP  
League City, Texas  
USA

*Andrea Bertocco*<sup>5</sup>

Global Products Science & Safety EMEA  
Herbalife Europe Limited  
Uxbridge  
England

<sup>2</sup> Chin-Hsiao Tseng received non-significant honoraria for serving on advisory boards and presentations from pharmaceutical companies, including Bristol-Myers-Squibb Company, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited.

<sup>3</sup> Randall S. Stafford provided expert testimony (ceased in 2011) for Mylan Pharmaceuticals, Morgantown, WV, manufacturer of generic drugs, including hydrochlorothiazide containing drugs.

<sup>4</sup> David Alexander represents clients who claim they have been injured by the drug pioglitazone. He is employed and sponsored by Williams Kherkher Hart Boundas, LLP, Houston Texas, USA.

<sup>5</sup> Andrea Bertocco is employed by Herbalife, where he served as regulatory Manager for Herbalife products containing Aloe vera, Goldenseal and Ginkgo biloba. He is sponsored by Herbalife Europe Limited, United Kingdom.

*Paul Dolin*<sup>6</sup>

Takeda Global Research & Development  
Centre (Europe) Ltd  
London  
England

*Olaf Kelber*<sup>7</sup>

World Self-Medication Industry  
Steigerwald Arzneimittelwerk GmbH  
Darmstadt  
Germany

*Egon Koch*<sup>8</sup>

World Self-Medication Industry  
Dr. Willmar Schwabe GmbH & Co. KG  
Karlsruhe  
Germany

Yann Grosse (*Responsible Officer, Rapporteur  
Cancer in Experimental Animals*)

Neela Guha (*Rapporteur Cancer in Humans*)

Kate Z. Guyton

Béatrice Lauby-Secretan (*Rapporteur  
Exposure Data*)

Ho-Sun Lee

Dana Loomis (*Rapporteur Cancer in Humans*)

Heidi Mattock (*Scientific Editor*)

Douglas Puricelli Perin

Mónica S. Sierra

Kurt Straif (*Head of Programme*)

Jiri Zavadil

## Administrative Assistance

Sandrine Egraz

Brigitte Kajo

Michel Javin

Annick Leroux

Helene Lorenzen-Augros

## IARC Secretariat

Melina Arnold

Robert Baan (*Senior Visiting Scientist*)

Helen Bailey

Lamia Benbrahim-Tallaa (*Rapporteur  
Mechanistic and Other Relevant Data*)

Véronique Bouvard (*Rapporteur Exposure  
Data*)

Fatiha El Ghissassi (*Rapporteur Mechanistic  
and Other Relevant Data*)

Akram Ghantous

## Production Team

Elisabeth Elbers

Solène Quennehen

Dorothy Russell

---

<sup>6</sup> Paul Dolin is employed and sponsored by Takeda Pharmaceutical Company Limited, Europe, manufacturing pioglitazone-containing and other pharmaceutical drugs. He holds stock of pharmaceutical companies marketing drugs that are reviewed at this meeting.

<sup>7</sup> Olaf Kelber is employed by Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, manufacturing herbal medicines. He is sponsored by the World-Self-Medication Industry (WSMI), France.

<sup>8</sup> Egon Koch is employed by Dr. Wilmar Schwabe GmbH & Co KG, Karlsruhe, Germany. He provides expert testimony with respect to the commercialization of Ginkgo biloba extracts. He is sponsored by the World-Self-Medication Industry (WSMI), France.